Answers are grounded in this paper and cite their sources.
Clinical validation demonstrates CD16b's effectiveness as a biomarker for GPI deficiencies, suggesting improved diagnostic processes.
Measurement of granulocyte CD16b provides a reliable and rapid screening method for IGD that complements genetic testing. Implementation of this assay by a commercial provider, together with validated cutoffs, enables nationwide, insurance-covered diagnostic testing and functional confirmation of GPI pathway gene variants, representing a significant advance in IGD diagnosis.
No takes yet. Share an insight, caveat, or question.
Tanigawa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: